search
Back to results

The LIVMOR Data Collection Study for the Development and Validation of L-1000AF System

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
L-1000AF System
Sponsored by
LIVMOR, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Atrial Fibrillation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Willing, able and sufficiently motivated to attend all study visits and participate in all study activities; and
  • Physically and mentally capable of providing informed consent and are at least 18 years of age or of legal age to provide consent as required by local and national requirements.

Exclusion Criteria:

  • Has any unstable or significant medical condition that is likely to interfere with study procedures or subjects medical care;
  • Has any implantable electronic medical device;
  • Has significant hearing, visual or cognitive impairment as determined by the Investigator; and
  • Participating in any other clinical study without written consent from the Sponsor

Sites / Locations

  • VA North Texas Health Care System
  • Texas Health Dallas

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

L-1000AF System

Arm Description

Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation

Outcomes

Primary Outcome Measures

Concurrent Atrial Fibrillation
Simultaneous ECG monitoring indicating Atrial Fibrillation rhythm.
Detection of Atrial Fibrillation
A decision of Atrial Fibrillation detection in at least one 192-beat window.

Secondary Outcome Measures

Full Information

First Posted
September 24, 2019
Last Updated
September 24, 2019
Sponsor
LIVMOR, Inc.
Collaborators
Texas Health Dallas, North Texas Veterans Healthcare System
search

1. Study Identification

Unique Protocol Identification Number
NCT04104191
Brief Title
The LIVMOR Data Collection Study for the Development and Validation of L-1000AF System
Official Title
The LIVMOR Data Collection Study for the Development and Validation of L-1000AF System
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
July 27, 2017 (Actual)
Primary Completion Date
February 13, 2019 (Actual)
Study Completion Date
February 14, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LIVMOR, Inc.
Collaborators
Texas Health Dallas, North Texas Veterans Healthcare System

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes

5. Study Description

Brief Summary
The LIVMOR Data Collection Study is a multicenter, IDE Exempt Study to generate a library of device-specific signals collected noninvasively. The study was not designed to evaluate specific hypothesis or endpoint, rather it was intended for data collection purposes to generate a library of raw clinical data that were retrospectively used for the development and subsequently the validation of the L-1000AF System. The L-1000AF System is a wrist worn system intended to provide continuous remote monitoring of atrial fibrillation (AF) episodes. The system is intended for use under the care of a physician and is not intended for the diagnosis of AF.
Detailed Description
LIVMOR is developing a series of wearable medical device systems intended to promote general wellness and help subjects and physicians manage various diseases that can benefit from increased visibility of physical activity, sleep, weight, blood pressure, stress/recovery levels and cardiac rhythms. Data from human subjects is necessary to develop and validate LIVMOR devices. LIVMOR completed a multicenter, IDE Exempt Study to generate a library of device-specific signals collected non-invasively using components of the LIVMOR system and simultaneously acquired with ECG Holter data using a commercially available Holter monitor. Data from the analysis of the Holter monitor was adjudicated by physicians skilled in the analysis and interpretation of ECGs compared to the analysis from the LIVMOR AF Detection Algorithm to establish the sensitivity and specificity of the algorithm for detection of AF in comparison to ground truth. The study was not designed to evaluate specific hypotheses or endpoint, rather it was intended for data collection purposes to generate a library of raw clinical data that were retrospectively used for the development and subsequently the validation of the L-1000AF System.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
271 (Actual)

8. Arms, Groups, and Interventions

Arm Title
L-1000AF System
Arm Type
Experimental
Arm Description
Software device on a wearable device used to detect irregular heart rhythms suggestive of Atrial Fibrillation
Intervention Type
Device
Intervention Name(s)
L-1000AF System
Intervention Description
The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
Primary Outcome Measure Information:
Title
Concurrent Atrial Fibrillation
Description
Simultaneous ECG monitoring indicating Atrial Fibrillation rhythm.
Time Frame
10 minutes
Title
Detection of Atrial Fibrillation
Description
A decision of Atrial Fibrillation detection in at least one 192-beat window.
Time Frame
10 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Willing, able and sufficiently motivated to attend all study visits and participate in all study activities; and Physically and mentally capable of providing informed consent and are at least 18 years of age or of legal age to provide consent as required by local and national requirements. Exclusion Criteria: Has any unstable or significant medical condition that is likely to interfere with study procedures or subjects medical care; Has any implantable electronic medical device; Has significant hearing, visual or cognitive impairment as determined by the Investigator; and Participating in any other clinical study without written consent from the Sponsor
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tony Das, MD
Organizational Affiliation
Texas Health Dallas
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Subhash Banerjee, MD
Organizational Affiliation
North Texas Veterans Healthcare System
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ken Persen
Organizational Affiliation
LIVMOR, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
VA North Texas Health Care System
City
Dallas
State/Province
Texas
ZIP/Postal Code
75216
Country
United States
Facility Name
Texas Health Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The LIVMOR Data Collection Study for the Development and Validation of L-1000AF System

We'll reach out to this number within 24 hrs